These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 25123357)

  • 1. Re-irradiation of recurrent glioblastoma multiforme using 11C-methionine PET/CT/MRI image fusion for hypofractionated stereotactic radiotherapy by intensity modulated radiation therapy.
    Miwa K; Matsuo M; Ogawa S; Shinoda J; Yokoyama K; Yamada J; Yano H; Iwama T
    Radiat Oncol; 2014 Aug; 9():181. PubMed ID: 25123357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.
    Grosu AL; Weber WA; Franz M; Stärk S; Piert M; Thamm R; Gumprecht H; Schwaiger M; Molls M; Nieder C
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):511-9. PubMed ID: 16168843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypofractionated high-dose irradiation with positron emission tomography data for the treatment of glioblastoma multiforme.
    Miwa K; Matsuo M; Ogawa S; Shinoda J; Asano Y; Ito T; Yokoyama K; Yamada J; Yano H; Iwama T
    Biomed Res Int; 2014; 2014():407026. PubMed ID: 24977151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of [11C]methionine positron emission tomography for target definition of glioblastoma multiforme in radiation therapy planning.
    Matsuo M; Miwa K; Tanaka O; Shinoda J; Nishibori H; Tsuge Y; Yano H; Iwama T; Hayashi S; Hoshi H; Yamada J; Kanematsu M; Aoyama H
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):83-9. PubMed ID: 21095072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amino-acid PET versus MRI guided re-irradiation in patients with recurrent glioblastoma multiforme (GLIAA) - protocol of a randomized phase II trial (NOA 10/ARO 2013-1).
    Oehlke O; Mix M; Graf E; Schimek-Jasch T; Nestle U; Götz I; Schneider-Fuchs S; Weyerbrock A; Mader I; Baumert BG; Short SC; Meyer PT; Weber WA; Grosu AL
    BMC Cancer; 2016 Oct; 16(1):769. PubMed ID: 27716184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
    Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
    Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of 11C-methionine positron emission tomography/computed tomography on radiation therapy planning and prognosis in patients with primary brain tumors.
    Schinkelshoek M; Lopci E; Clerici E; Alongi F; Mancosu P; Rodari M; Navarria P; van der Hiel B; Scorsetti M; Chiti A
    Tumori; 2014; 100(6):636-44. PubMed ID: 25688497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical value of [¹¹C]methionine PET for stereotactic radiation therapy with intensity modulated radiation therapy to metastatic brain tumors.
    Miwa K; Matsuo M; Shinoda J; Aki T; Yonezawa S; Ito T; Asano Y; Yamada M; Yokoyama K; Yamada J; Yano H; Iwama T
    Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1139-44. PubMed ID: 22520479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous integrated boost technique by helical tomotherapy for the treatment of glioblastoma multiforme with 11C-methionine PET: report of three cases.
    Miwa K; Matsuo M; Shinoda J; Oka N; Kato T; Okumura A; Ueda T; Yokoyama K; Yamada J; Yano H; Yoshimura S; Iwama T
    J Neurooncol; 2008 May; 87(3):333-9. PubMed ID: 18217211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated-boost IMRT or 3-D-CRT using FET-PET based auto-contoured target volume delineation for glioblastoma multiforme--a dosimetric comparison.
    Piroth MD; Pinkawa M; Holy R; Stoffels G; Demirel C; Attieh C; Kaiser HJ; Langen KJ; Eble MJ
    Radiat Oncol; 2009 Nov; 4():57. PubMed ID: 19930657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of hypofractionated intensity-modulated irradiation in the treatment of glioblastoma multiforme: preliminary results of a prospective trial.
    Sultanem K; Patrocinio H; Lambert C; Corns R; Leblanc R; Parker W; Shenouda G; Souhami L
    Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):247-52. PubMed ID: 14697445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-grade glioma radiation therapy target volumes and patterns of failure obtained from magnetic resonance imaging and 18F-FDOPA positron emission tomography delineations from multiple observers.
    Kosztyla R; Chan EK; Hsu F; Wilson D; Ma R; Cheung A; Zhang S; Moiseenko V; Benard F; Nichol A
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1100-6. PubMed ID: 24161427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme.
    Lee IH; Piert M; Gomez-Hassan D; Junck L; Rogers L; Hayman J; Ten Haken RK; Lawrence TS; Cao Y; Tsien C
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):479-85. PubMed ID: 18834673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrated boost IMRT with FET-PET-adapted local dose escalation in glioblastomas. Results of a prospective phase II study.
    Piroth MD; Pinkawa M; Holy R; Klotz J; Schaar S; Stoffels G; Galldiks N; Coenen HH; Kaiser HJ; Langen KJ; Eble MJ
    Strahlenther Onkol; 2012 Apr; 188(4):334-9. PubMed ID: 22349712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
    Chen C; Damek D; Gaspar LE; Waziri A; Lillehei K; Kleinschmidt-DeMasters BK; Robischon M; Stuhr K; Rusthoven KE; Kavanagh BD
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1066-74. PubMed ID: 20932651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma.
    Tsien CI; Brown D; Normolle D; Schipper M; Piert M; Junck L; Heth J; Gomez-Hassan D; Ten Haken RK; Chenevert T; Cao Y; Lawrence T
    Clin Cancer Res; 2012 Jan; 18(1):273-9. PubMed ID: 22065084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of FET-PET imaging for target volume definition in patients with gliomas treated with conformal radiotherapy.
    Rieken S; Habermehl D; Giesel FL; Hoffmann C; Burger U; Rief H; Welzel T; Haberkorn U; Debus J; Combs SE
    Radiother Oncol; 2013 Dec; 109(3):487-92. PubMed ID: 23953407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relapse patterns after radiochemotherapy of glioblastoma with FET PET-guided boost irradiation and simulation to optimize radiation target volume.
    Piroth MD; Galldiks N; Pinkawa M; Holy R; Stoffels G; Ermert J; Mottaghy FM; Shah NJ; Langen KJ; Eble MJ
    Radiat Oncol; 2016 Jun; 11():87. PubMed ID: 27342976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma.
    Iuchi T; Hatano K; Kodama T; Sakaida T; Yokoi S; Kawasaki K; Hasegawa Y; Hara R
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):793-800. PubMed ID: 24495592
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Lakomý R; Lojová M; Souckova L; Hynkova L; Polachova K; Vasina J; Demlová R; Poprach A; Sana J; Prochazka T; Smrcka M; Fadrus P; Jancalek R; Selingerova I; Belanova R; Slampa P; Pospisil P; Kazda T
    BMC Cancer; 2024 Jun; 24(1):736. PubMed ID: 38879476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.